All Solid Tumors

Cancer Type

Tumor Tissue (FFPE)

Sample Type

8 Working Days

Turnaround Time ¹

ACTDrug®+ is an NGS-based test, which sequences 40 druggable genes, 13 fusion genes, and more than 350 fusion transcripts simultaneously from cancer specimens.

Precision Medicine to Plan Better Treatment

Precision Medicine to Plan Better Treatment

Every cancer is associated with a unique combination of genomic changes. Furthermore, different cells within a tumor may harbor different genomic abnormalities. Comprehensive genomic profiling can identify such changes in cell signaling pathways by detecting prognostic and predictive biomarkers. This information can then be used to facilitate treatment decisions. This process is known as precision medicine.

Learn More

Why ACT Genomics?

Humane Process

Avoids multiple biopsies and the time cost associated with single-gene testing, as only a small specimen is required for the simultaneous detection of various fusion genes.

Ideal Treatment

Nominates proper targeted options.

Smart Budgeting

Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting of funds.

Learn More

How to Ensure Your Treatment is Aimed at the Bull's Eye

As with any big decision in life, you cannot be too careful, and this is very much the case with your targeted therapy. There is often more than one target in a tumor, and a treatment strategy is to guess the driver-gene target that will result in a successful treatment. If the chosen gene target is found not to be the driver gene of the tumor, then another target needs to be guessed to bring the tumor under control. This guesswork process continues until the correct driver gene is chosen as the target. This process is both inefficient and expensive. Cancer genomic profiling enables major targets to be revealed all at once, such as EGFR, ALK, ROS1, etc, and then by identifying the driver gene, you will be aiming at the bull's eye and increase the chances of having a successful treatment.

Common Problems in Cancer Treatment

  • Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results
  • Complications and metastases make it difficult to determine an appropriate drug
  • Ineffective treatment and cancer relapse after targeted therapy

Diagnostic Solutions for Various Cancers

Through next-generation sequencing (NGS), ACTDrug®+ targeted genomic profiling decodes 40 cancer genes to map drug options based on thorough clinical research, is not limited to a single clinical treatment guideline and determines the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate. ACTDrug®+ is suitable for breast, lung, colon cancers and other solid tumors. As single gene testing only provides very limited results, NGS genomic profiling can detect any special genomic mutations to result in a more effective treatment; if recurrence or metastases are found, treatment can be modified according to the NGS genomic profiling result to overcome drug resistance.

Who Is Suitable for ACTDrug®+?

  • All solid tumor patients including common cancer and rare cancer


No items found.

Disclaimers / Footnotes

  1. Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.

Book a Test

Explore the immense possibilities and promising future of precision medicine. Together, let us unlock the power of genomic testing and personalize cancer care for the most effective treatment.

Get Started